MarketPR
Novo Nordisk stock tumbled on Monday after the weight-loss drug maker set out 2030 goals that failed to excite investors.
The market reaction reflects a broader skepticism toward the company's ability to deliver a visible turnaround in its core operations.
Shares fell in the session as traders weighed the new targets against current supply chain realities. The catalyst for the sell-off was the release of the company's long-term targets.
Novo Nordisk outlined specific goals for the year 2030, aiming to demonstrate progress in its weight-loss drug manufacturing.
Keep reading